The metabolic syndrome and schizophrenia: the latest evidence and nursing guidelines for management.
The introduction of second-generation antipsychotic drugs for the treatment of schizophrenia has provided significant benefits for clients experiencing this disorder. While they have been found effective in reducing psychotic symptoms, there is evidence that these drugs are also linked with a group of side effects commonly known as the metabolic syndrome. Mental health nurses are well positioned to prevent, detect and/or manage the development of this problematic constellation of symptoms. Guidelines for practice can be useful in prevention and management of the syndrome and enhance nursing care of clients who are taking second-generation antipsychotics.
Usher
K
K
School of Nursing Sciences, James Cook University, Townsville, Qld, Australia. kim.usher@jcu.edu.au
Foster
K
K
Park
T
T
D014150:Antipsychotic Agents / Q000009:adverse effects*; D016903:Drug Monitoring; D019317:Evidence-Based Medicine; D015444:Exercise; D005247:Feeding Behavior; D006301:Health Services Needs and Demand; D006801:Humans; D008019:Life Style; D024821:Metabolic Syndrome / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control*; D024802:Nurse's Role; D009730:Nursing Assessment; D017410:Practice Guidelines as Topic; D015995:Prevalence; D011322:Primary Prevention; D011568:Psychiatric Nursing / Q000458:organization & administration*; D018570:Risk Assessment; D012307:Risk Factors; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy; D012907:Smoking / Q000009:adverse effects; D000074606:Smoking Prevention; D013315:Stress, Psychological / Q000150:complications / Q000517:prevention & control
D014150:Antipsychotic Agents